# Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

> **NCT07329894** · PHASE1 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** XH001 injection
- **DRUG:** Tumor vaccine-induced specific T-cell injection

## Key facts

- **NCT ID:** NCT07329894
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-08
- **Final completion:** 2029-10
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07329894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07329894, "Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07329894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*